Development of Intra-Articular Drug Delivery to Alter Progression of Arthritis Following Joint Injury
Revised annual rept. 15 Sep 2011-14 Mar 2012
DUKE UNIV DURHAM NC
Pagination or Media Count:
DESIGN A novel injectable and in situ forming drug depot based on thermally-responsive elastin-like polypeptide ELP will be used to deliver an anti-inflammatory drug to an injured joint and provide slow release over time. METHODS Loaded ELP depots were incubated at 37C with or without 10 serum to quantify in vitro drug release over 1 week. Drug release was quantified by UV-Vis spectroscopy for serum-free conditions and by commercially available ELISA kits RD Systems in the presence of serum. Bioactivity of released sTNFRII was evaluated via the murine L929 cytoprotection assay, an industry standard. DATA ANALYSIS Means and SEM n4 of released drug were calculated at each time point 1, 2, 3, 24, 48, 72, 96, and 168 hours, and data were fit to a nonlinear model of one dimensional steady-state diffusion. FINDINGS Over 7 days, 80 of IL1Ra was released from the ELP depot in serum-free and serum-containing conditions. For sTNFRII, 8 of loaded drug was released from the ELP depot in serum-free conditions, compared to 79 in the presence of serum. These findings confirm the mechanism that drug is released from the degrading drug depot. Released sTNFRII was found to retain activity against TNF945 at each time point.
- Medicine and Medical Research